Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema

• Status: Terminated
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether intravitreous bevacizumab or intravitreous triamcinolone acetonide are effective and safe in the treatment of uveitic macular oedema

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Clinic of Barcelona
• Treatments: Bevacizumab; Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

• adult patients with uveitis or retinal vasculitis with unilateral or bilateral macular oedema

• with macular thickness > 250 micra using OCT

• visual acuity at least 20/200

• with stable treatment with oral prednisone at least during 3 months, either oral ciclosporin or other immunomodulator to treat intraocular inflammatory disease

• patient that can follow study's requirements

• patient who consents to participate

Exclusion Criteria:

• presence of corneal or crystalline opacity preventing observation of fundus of eye

• patients requiring ocular surgery in next 3 months

• one-eyed

• pregnancy and child breastfeeding

• previous history of glaucoma

• on treatment woth an experimental ocular drug

• previous thromboembolism or receiving oral anticoagulant treatment

• vitrectomy

• patients with proved tractional macular pathology associated to macular oedema